Carl read the papersWhat it actually is
Amylin is the satiety hormone your pancreas releases alongside insulin at every meal. Eloralintide is a once-weekly synthetic agonist of its receptor — same target family as cagrilintide, different engineering brief.
The brief was selectivity. Cagrilintide is a dual amylin/calcitonin agonist; eloralintide was designed to activate the amylin receptor and largely leave the calcitonin receptor alone. The theory was that a lot of the GI misery in this class comes from the off-target half.
How it’s thought to work
- Selective amylin receptor agonism — Activates the amylin receptor complex without meaningful calcitonin receptor activity — the design difference that separates it from cagrilintide.
- Meal termination — Amylin signals that the meal is finished. People describe stopping earlier rather than never feeling hungry.
- Hedonic appetite — Amylin signalling leans on reward-driven eating, which is a different problem from the homeostatic hunger GLP-1s address.
- Once-weekly kinetics — Engineered for a long enough half-life to hold a weekly schedule.
What the research says
Genuinely strong for something this new: phase 2, 263 adults, 48 weeks. Every dose arm beat placebo, with mean weight reductions of 9.5% to 20.1% against 0.4% on placebo. Results were presented at ObesityWeek 2025 and published simultaneously in The Lancet. The 20.1% figure came from the 9 mg arm.
- Phase 2 (n=263, 48 wks) — 9.5%–20.1% mean weight reduction vs 0.4% placebo.
- Adverse events were mostly mild-to-moderate GI plus fatigue, weighted toward the higher-dose arms.
- Improvements also reported across waist circumference, blood pressure, lipids, glycaemic control and inflammatory markers.
- Selectivity for the amylin receptor is the design premise — and the tolerability data is the argument that it worked.
Watch: Eloralintide explained
Video by Mark Charbonneau, PhD on YouTube. Not affiliated with Peptide Carl and not an endorsement — included because a second explanation of the same mechanism is often what makes it click.
Reported protocols
These are the doses the peptide community actually reports running (Reddit & forums), alongside published research — logged for education, not as a recommendation to use.
| Parameter | Commonly reported range |
|---|---|
| Trial doses | Weekly, escalating; the top arm ran to 9 mg weekly by week 48 |
| Community dose | Far below trial arms — this compound is new enough that no settled community protocol exists yet |
| Frequency | Once weekly |
| Route | Subcutaneous — abdomen, thigh or upper arm, rotating sites |
| Cycle | The trial ran 48 weeks continuously |
| Community tip | The consistent report on every amylin compound is the same: escalate slowly. Nausea tracks how fast you climb, not where you end up. |
Common use cases
| Goal | Community protocol notes |
|---|---|
| Appetite / satiety | weekly, escalated gradually — trial arms ran up to 9 mg |
| Alternative to a dual agonist | for people who could not tolerate cagrilintide's GI profile |
| Added to a GLP-1 | second mechanism rather than more of the first — no trial data on this pairing |
Mixing it (reconstitution)
Freeze-dried peptides must be reconstituted with bacteriostatic water before they can be measured. Carl’s calculator turns “mg in the vial + ml of water + target dose” into “units on the syringe” — and tells you how long the vial lasts.
→ Open the Reconstitution Calculator
Injection & handling
Subcutaneous, once weekly — abdomen, thigh or upper arm, rotating sites. The long half-life is what allows weekly dosing and also means a dose you regret stays with you for days, which is the whole argument for climbing slowly. Reconstituted, keep it cold and out of the light.
Stacks it appears in
- With a GLP-1 — The same different-pathway logic behind CagriSema. No trial data covers this combination for eloralintide specifically.
- Alone — Phase 2 tested it as monotherapy, which is the only pattern with data behind it.
